Novo Nordisk's Friday Rout: A Failed Cardiovascular Bet and a Legal Cloud That Won't Lift

Novo Nordisk's Ziltivekimab misses primary endpoint in Phase-3 trial, while a US court allows securities-fraud suit, sending shares down 8.48%.

The Danish pharmaceutical giant entered the weekend nursing its deepest one-day share decline in nearly five months, after a pivotal heart-disease study came up empty and a US court refused to bury a securities-fraud lawsuit. Shares closed Friday at EUR 40.90, down 8.48 percent in German trading — a slide that leaves the stock hovering just 1.35 percent above its 200-day moving average of EUR 40.35, a level chart watchers have flagged as a key support zone.

The sell-off caps a bruising stretch for Novo Nordisk, which has now surrendered 7.10 percent of its value since the start of the year. The twin blows — a failed Phase-3 trial and a legal setback in New Jersey — arrived on the same day, compounding what was already shaping up to be a pivotal quarter for the company.

A Null Result That Stings

The more consequential development came from the ZEUS study, a placebo-controlled Phase-3 trial that enrolled more than 6,300 patients with atherosclerotic cardiovascular disease, chronic kidney disease, and elevated inflammatory markers (hsCRP of at least 2 mg/l). Participants received monthly 15-milligram doses of Ziltivekimab, an antibody designed to block the IL-6 inflammatory pathway. The drug's primary endpoint — reducing major adverse cardiovascular events such as cardiovascular death, non-fatal heart attack, or stroke — was missed with a hazard ratio of 0.99, meaning the treatment performed statistically no better than placebo.

What makes the failure particularly frustrating for the company is that the drug did exactly what it was supposed to do biologically. Ziltivekimab reliably suppressed both Interleukin-6 and hsCRP, yet that anti-inflammatory effect never translated into clinical benefit. The study also recorded a higher incidence of serious infections in the treatment arm, while overall mortality was unchanged between groups.

The setback carries strategic weight beyond the trial itself. Ziltivekimab, acquired through the 2020 purchase of Corvidia Therapeutics for USD 725 million plus up to USD 2.1 billion in potential milestone payments, was meant to give Novo Nordisk a credible growth engine outside its dominant GLP-1 franchise in obesity and diabetes. That diversification thesis has now been dealt a serious blow — at least for the foreseeable future.

Novo Nordisk has said it will take a non-cash impairment charge in the third quarter as a result, while insisting its full-year 2026 guidance remains intact. Chief Scientific Officer Martin Holst Lange told CNBC the outcome does not alter the company's strategic commitment to cardiology. Two other Ziltivekimab trials — HERMES, examining the drug in heart failure, and ARTEMIS, in acute heart attack — remain ongoing, with results expected in the first half of 2027. Those readouts may determine whether the cardiology program can be salvaged.

The Courtroom Front

Adding to Friday's pressure was a ruling from Judge Robert Kirsch in New Jersey, who allowed an investor lawsuit alleging securities fraud to proceed. The plaintiffs claim Novo Nordisk made misleading statements about CagriSema, its next-generation weight-loss candidate. At the heart of the allegations: the company failed to disclose significant protocol changes to the REDEFINE-1 study, in which patients were permitted to self-adjust their doses because gastrointestinal side effects were limiting tolerability. That adjustment, plaintiffs argue, masked the drug's true safety and efficacy profile from the market. While the court dismissed some claims, the core allegations survived — leaving another overhang on the stock.

Technicals and the Analyst Divide

The RSI reading of 41.8 points to heavy selling pressure, though it has not yet reached oversold territory — suggesting the stock may have more room to fall before technical buyers step in. The Friday close, however, still sits above the 200-day average, indicating the medium-term uptrend has been dented but not broken.

Analysts are split on how to interpret the damage. Jefferies and Citi both called the sell-off overdone, while simultaneously acknowledging the strategic negative. The market erased more than USD 30 billion in value on Friday — a reaction that some argue is disproportionate to the failed drug's actual revenue contribution. The consensus rating on the stock remains "Hold," with a price target around USD 47.

What's Next

Investors now have a clear date on the calendar: Wednesday, August 5, when Novo Nordisk reports first-half results. The focus will be on oral Wegovy sales following its EU approval in mid-July, along with a higher-dose 7.2-milligram Wegovy variant. Also in play: whether the company's adjusted operating profit guidance holds despite the expected third-quarter impairment. Consensus estimates point to earnings per share of USD 0.81, down 16.5 percent year over year, while other forecasts project revenue of DKK 71.5 billion and EPS of DKK 5.04 — both below prior-year levels.

Meanwhile, the competitive landscape keeps shifting. Novo Nordisk filed a lawsuit against Eli Lilly in late July over allegedly misleading advertising for its GLP-1 products, and the company is running a share buyback program of up to USD 2.3 billion, of which roughly USD 1.10 billion had been deployed as of July 24. The August report will show whether the GLP-1 franchise can continue to carry the load — or whether the ZEUS failure marks the beginning of a more difficult chapter.